Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois H Jacques

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Cognitive evolution in natalizumab-treated multiple sclerosis patientsFrancois H Jacques, Brian T Harel, Adrian J Schembri, et al.
Glia|April 14, 2012
Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosisJennifer L Berard, Juan G Zarruk, Nathalie Arbour, et al.
Neuro-Oncology Advances|October 4, 2021
Avelumab in newly diagnosed glioblastomaFrancois H Jacques, Garth Nicholas, Ian A J Lorimer, et al.
Plos One|October 12, 2016
Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal FluidDeepak K Kaushik, Heather Y F Yong, Jennifer N Hahn, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Cognitive evolution in natalizumab-treated multiple sclerosis patientsFrancois H Jacques, Brian T Harel, Adrian J Schembri, et al.
Glia|April 14, 2012
Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosisJennifer L Berard, Juan G Zarruk, Nathalie Arbour, et al.
Neuro-Oncology Advances|October 4, 2021
Avelumab in newly diagnosed glioblastomaFrancois H Jacques, Garth Nicholas, Ian A J Lorimer, et al.
Plos One|October 12, 2016
Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal FluidDeepak K Kaushik, Heather Y F Yong, Jennifer N Hahn, et al.
Pageof 1